ArticleScientific reports2026
Proof of concept for aqueous two-phase system-based extraction of cell-free DNA from plasma for liquid biopsy applications.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Efficient extraction of circulating cell-free DNA (cfDNA) from plasma is critical for liquid biopsy applications, but remains challenging due to cfDNA's short fragment size, low concentration, and the presence of interfering proteins and genomic DNA. This study presents a simple extraction process based on aqueous two-phase system (ATPS) capture and reverse elution purification as a potentially lysis-free alternative to adsorption-based methods. Short DNA fragments selectively partitioned into the salt-rich bottom phase, achieving up to 65% recovery after purification while removing 99.7% of plasma proteins. Reverse elution enabled efficient desalting and up to fourfold DNA concentration under mild, aqueous conditions. The extracts showed no qPCR inhibition and displayed a cfDNA-like size profile with a cutoff around 750 bp, indicating selective enrichment of short fragments. Although the total yield was slightly lower than that of the QIAamp Circulating Nucleic Acid Kit (QIAGEN), the ATPS workflow substantially reduced processing time, equipment needs, and cost. Next-generation sequencing of cfDNA reference material extracted from DNA-free plasma confirmed compatibility with library preparation and sequencing workflows, providing proof of concept for a simplified cfDNA extraction strategy for amplification-based liquid biopsy applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.